# to-BBB technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/to-bbb-technologies

- Industry: Pharmaceuticals
- Headquarters: Leiden, Netherlands
- Website: www.tobbb.com
- Total disclosed funding: $24M
- Latest round: Series C (Jun 30, 2014)
- Investors on record: 4

## About

to-BBB technologies BV specializes in innovative drug delivery systems aimed at addressing brain and eye diseases through proprietary technologies that enhance therapeutic efficacy.Founded in 2003 and headquartered in Leiden, Netherlands, to-BBB technologies BV develops advanced drug delivery systems. The company has successfully completed a total of 12 deals, with its most recent being a Series C round of EUR 10.000 mn raised on June 30, 2014, led by Antea. The firm does not have any reported subsidiaries or parent companies, and further details about the founders or their past ventures are not available.2-BBB Medicines B.V. specializes in the development of advanced drug delivery systems specifically targeting brain and eye diseases. The company's core offerings include proprietary formulations based on G-Technology®, which employs CNS-targeted liposomes to enhance the delivery of therapeutics across the blood-brain barrier and blood-retina barrier. With two lead programs currently in clinical development—2B3-101 for brain cancer and 2B3-201 for neuro-inflammatory diseases—2-BBB aims to address critical unmet medical needs in these challenging areas. The end-users of these products primarily comprise patients suffering from debilitating neurological conditions, as well as healthcare providers seeking innovative treatment options. While the company is headquartered in the Netherlands, it actively seeks to penetrate broader international markets where demand for effective treatments for CNS and ocular disorders exists.The revenue model of 2-BBB Medicines B.V. is structured around partnerships and collaborations within the pharmaceutical industry, focusing on B2B transactions. The company engages with pharmaceutical firms or research institutions to co-develop and commercialize its proprietary drug delivery technologies. Revenue generation stems from licensing agreements or joint ventures related to its flagship programs, including 2B3-101 and 2B3-201, involving upfront payments, milestone payments upon achieving clinical or regulatory targets, and royalties on sales post-commercialization. Specific pricing plans for each product are not disclosed, but the nature of CNS-targeted drug delivery systems suggests a value-based pricing strategy.In June 2014, to-BBB raised EUR 10.000 mn in Series C financing, which is expected to support its clinical development programs, specifically for 2B3-101 and 2B3-201. The company is focused on expanding its market reach and aims to penetrate new geographic markets where demands for CNS and ocular disorder treatments exist. While specific upcoming products were not outlined, to-BBB is likely channeling its recent funding to enhance its research and development efforts to bring innovative solutions to market.

## Funding rounds

- Series C, Jun 30, 2014, $14M — Antea
- Series B, Feb 3, 2011, $5.5M — Aescap Venture, O-Bank, Antea, Jonghoud International BV
- Series A, Jul 6, 2007, $5.4M — Aescap Venture
- Seed, Aug 1, 2004 — Antea

## Investors

- Antea (https://capitalatlas.ai/funds/antea) — Seed, Series B, Series C
- Aescap Venture (https://capitalatlas.ai/funds/aescap-venture) — Series A, Series B
- O-Bank (https://capitalatlas.ai/funds/o-bank) — Series B
- Jonghoud International BV — Series B